Funds advised by Yana Investment Partners participated with Gyrus Capital and the management of Essential Pharma in the acquisition of 100% of the shares of the Essential Pharma Group from the founder family. UK-based Essential Pharma is a speciality generic pharma business focussed on CNS and other niche pharmaceutical products. Essential Pharma addresses the problem of drug shortages by ensuring the continued supply of low volume and legacy drugs with high clinical importance which is at risk of discontinuation and stockouts.
Essential Pharma plans to continue to grow the business through further product acquisitions in Europe, and potential add-ons.
Yana Investment Partners worked alongside Gyrus Capital, a Geneva-based investment firm focusing on long-term sustainable growth sectors.